Letters To The Editor
Copyright ©2010 Baishideng. All rights reserved.
World J Diabetes. Jul 15, 2010; 1(3): 99-100
Published online Jul 15, 2010. doi: 10.4239/wjd.v1.i3.99
Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes
Hidekatsu Yanai, Yoshinori Masui, Reo Yoshikawa, Junwa Kunimatsu, Hiroshi Kaneko
Hidekatsu Yanai, Yoshinori Masui, Reo Yoshikawa, Junwa Kunimatsu, Department of Internal Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba 272-8516, Japan
Hiroshi Kaneko, Department of Rheumatology, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba 272-8516, Japan
Author contributions: Yanai H and Kaneko H contributed to the conception, writing and editing of the paper; Masui Y, Yoshikawa R and Kunimatsu J treated the patient presented in the paper and contributed to data collection.
Correspondence to: Hidekatsu Yanai, MD, PhD, FACP, Department of Internal Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba 272-8516, Japan. dyanai@hospk.ncgm.go.jp
Telephone: +81-47-3733501 Fax: +81-47-3721858
Received: April 20, 2010
Revised: June 22, 2010
Accepted: June 29, 2010
Published online: July 15, 2010
Abstract

The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 inhibitor, showing that the DPP-4 inhibitors may be an effective and safe oral anti-diabetic drug for steroid-induced diabetes.

Keywords: Dipeptidyl peptidase-4; Nateglinide; Sitagliptin; Steroid-induced diabetes